Other
Bladder Cancer Advocacy Network
Total Trials
4
Recruiting
2
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
Failure Rate
0.0%
0 terminated/withdrawn out of 4 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed trials have results
Key Signals
2 recruiting1 with results
Enrollment Performance
Analytics
Phase 2
2(50.0%)
N/A
2(50.0%)
4Total
Phase 2(2)
N/A(2)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (4)
Showing 4 of 4 trials
NCT06503614Phase 2Recruiting
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
Role: collaborator
NCT06040762Not ApplicableRecruiting
A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial
Role: collaborator
NCT02451423Phase 2Completed
Neoadjuvant Atezolizumab in Localized Bladder Cancer
Role: collaborator
NCT02643043Not ApplicableCompleted
UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch
Role: collaborator
All 4 trials loaded